Study Used To Win FDA Nod For Amgen's Vasculitis Drug Is Under Review

Study Used To Win FDA Nod For Amgen's Vasculitis Drug Is Under Review The FDA has proposed pulling Tavneos from the market. Now, the New England Journal of Medicine is investigating allegations that the drug was approved based on manipulated data, Bloomberg reports. Tavneos treats a rare form of blood vessel inflammation called ANCA-associated vasculitis. https://kffhealthnews.org/morning-breakout/pharma-and-tech-060826/